CLOSE
SITE MAP
イノベーションが
生まれる「まち」。

2021/08/27

Pitch 4-1 :Cellusion Inc. -Corneal endothelial regenerative medicine utilizing iPSC derived CECSi cells-

【Corneal endothelial regenerative medicine utilizing iPSC derived CECSi cells】

⇒The abstract is available in text.
Abstract of Cellucion.pdf

Profile

Shin Hatou has performed corneal transplantation over decade after graduating Keio University School of Medicine. He became an assistant professor to a lecturer in Keio University, where he has researched on corneal endothelial regenerative therapy. In 2015, he founded Cellusion Inc. and has become the CEO.